CN106389454A - Compound erythromycin thiocyanate soluble powder for livestock and preparation method therefor - Google Patents
Compound erythromycin thiocyanate soluble powder for livestock and preparation method therefor Download PDFInfo
- Publication number
- CN106389454A CN106389454A CN201610770352.4A CN201610770352A CN106389454A CN 106389454 A CN106389454 A CN 106389454A CN 201610770352 A CN201610770352 A CN 201610770352A CN 106389454 A CN106389454 A CN 106389454A
- Authority
- CN
- China
- Prior art keywords
- erythromycin thiocyanate
- taurine
- erythromycin
- soluble powder
- thiocyanate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses compound erythromycin thiocyanate soluble powder for livestock. The compound erythromycin thiocyanate soluble powder for livestock is prepared from the following components in a mixing manner: erythromycin thiocyanate, taurine and the balance of auxiliary materials. The compound erythromycin thiocyanate soluble powder for livestock also can reinforce metabolism of liver on erythromycin thiocyanate and can relieve gastrointestinal discomfort symptoms, may caused by erythromycin thiocyanate irritation, of livestock.
Description
Technical field
The invention belongs to animal pharmaceuticals technical field, it is related to a kind of animal compound erythromycin thiocyanate soluble powder and its system
Preparation Method.
Background technology
Erythromycin thiocyanate belongs to macrolide antibiotics, is the rhodanate of erythromycin.This product is veterinary drug, for removing from office orchid
Family name's positive bacteria and the infection of mycoplasma；More as initial feed be used for synthesis of erythromycin, ROX, azithromycin, gram
Draw the macrolide antibiotics such as mycin.Antimicrobial spectrum is similar to parasiticin, to the staphylococcus aureus in gram positive bacteria,
The effect such as streptococcus, pneumococcus is relatively strong, also has certain effect to the Pasteurella in gram-negative bacteria, Brucella；Additionally,
This product is also effective to Mycoplasma, Richettsia, Leptospira, actinomyces, promise card bacterium.It is mainly used in resistant S grape ball
Severe infections caused by bacterium, hemolytic streptococcus, such as pneumonia, septicemia, endometritis, mastitis etc.；To Mycoplasma institute
The poultry chronic respiratory tract disease causing, swine mycoplasma pneumonia also have good therapeutic effect, are additionally operable to dog, the treatment of cat nocardiosis；Also
The white head and mouth fish disease of the fries such as green grass or young crops, grass, chain, flathead and fingerling, grass carp, black carp bacterial gill, silver carp, the white skin of bighead can be prevented and treated
Streptococcosis of disease and Tilapia mossambica etc..
?《Veterinary drug guide for use (chemicals volume)》Described in erythromycin thiocyanate be likely to be of hepatotoxicity wind agitation, show as courage
Juice deposits it is also possible to causing vomiting and suffering from diarrhoea.Erythromycin thiocyanate, as other macrolideses, has excitant, many
Often dose-dependent gastrointestinal disturbance (vomiting, diarrhoea, intestines pain etc.) after taking erythromycin orally in animal.And thiocyanic acid is red mould
Element be administered orally through animal after mainly through liver metabolism, and the not strong animal of liver function, can seriously reduce its medication effect, and sulphur
Cyanic acid erythromycin can not be shared with other alkaline drugs again.
Content of the invention
For solving above technical problem, present invention aim at providing a kind of animal compound erythromycin thiocyanate soluble powder
And preparation method thereof, find that taurine can not only be shared with erythromycin thiocyanate, and liver metabolism effect can also be strengthened, with
When can alleviate the uncomfortable symptom of the animal gastrointestinal tract that may cause due to medicine irritation.
Taurine of the present invention has strong liver cholagogic effect, can release cholestasia, be conducive to erythromycin thiocyanate to exist
Metabolism in liver；Taurine itself also has anti-inflammatory and refrigeration function, its mechanism of action be by maincenter 5-ht system or
The effect of catecholamine system is realized, and can reach perfect supplementary result to the antiphlogistic effects of erythromycin thiocyanate；In addition ox
Sulfonic acid can promote pituitary hormone secretion, activates pancreas function, thus improving the state of organism endocrine system, to organism metabolism with
Beneficial regulation, and there is the enhancing promoting organism immunity and antifatigue effect.
The object of the invention is realized in：
Described animal compound erythromycin thiocyanate soluble powder include by mass percentage erythromycin thiocyanate 5～
50%, taurine 5～10%, balance of auxiliary material.
Described auxiliary material is DEXTROSE ANHYDROUS, oral glucose, lactose, maltodextrin, plus beneficial powder, soluble starch in one
Plant or more than one combinations.
Its preparation process is：
(1) erythromycin thiocyanate, auxiliary material and taurine are weighed by described weight；
(2) first by erythromycin thiocyanate ultramicro grinding, Task-size Controlling is below 50 μm, standby；
(3) finally the material after smashing is mixed with taurine and auxiliary material, mix 30min.
The invention has the beneficial effects as follows：
In the present composition, taurine has strong liver cholagogic effect, can release cholestasia, thiocyanic acid can be conducive to red
Metabolism in liver for the mycin；Taurine itself also has antipyretic and antiinflammatory action, and its mechanism of action is by maincenter 5-ht
The effect of system or catecholamine system reduces body temperature, can reach perfectly supplementary effect to the antiphlogistic effects of erythromycin thiocyanate
Really；In addition taurine can promote pituitary hormone secretion, activates pancreas function, thus improving the state of organism endocrine system, right
Organism metabolism and beneficial regulation, and there is the enhancing promoting organism immunity and antifatigue effect.
The present invention a kind of animal compound erythromycin thiocyanate soluble powder and preparation method thereof, taurine can not only be with sulphur
Cyanic acid erythromycin shares, and can also strengthen the metabolism for erythromycin thiocyanate for the liver, alleviates due to medicine thorn simultaneously
Swash the uncomfortable symptom of the animal gastrointestinal tract that may cause.
Specific embodiment
With reference to embodiment, the invention will be further described.
Embodiment 1：
Prescription：
Erythromycin thiocyanate 5g
Taurine 5g
Glucose adds to 100g
Carry out according to the following steps：
(1) erythromycin thiocyanate, glucose and taurine are weighed by described weight；
(2) first by erythromycin thiocyanate ultramicro grinding, Task-size Controlling is below 50 μm, standby；
(3) finally the material after smashing is mixed with glucose and taurine, mix 30min
Embodiment 2：
Prescription：
Erythromycin thiocyanate 30g
Taurine 10g
Glucose adds to 100g
Carry out according to the following steps：
(1) erythromycin thiocyanate, glucose and taurine are weighed by described weight；
(2) first by erythromycin thiocyanate ultramicro grinding, Task-size Controlling is below 50 μm, standby；
(3) finally the material after smashing is mixed with glucose and taurine, mix 30min
Embodiment 3：
Prescription：
Erythromycin thiocyanate 50g
Taurine 10g
Glucose adds to 100g
Carry out according to the following steps：
(1) erythromycin thiocyanate, glucose and taurine are weighed by described weight；
(2) first by erythromycin thiocyanate ultramicro grinding, Task-size Controlling is below 50 μm, standby；
(3) finally the material after smashing is mixed with glucose and taurine, mix 30min
Embodiment 4：
Prescription：
Erythromycin thiocyanate 25g
Taurine 10g
Maltodextrin adds to 100g
Carry out according to the following steps：
(1) erythromycin thiocyanate, glucose and taurine are weighed by described weight；
(2) first by erythromycin thiocyanate ultramicro grinding, Task-size Controlling is below 50 μm, standby；
(3) finally the material after smashing is mixed with maltodextrin and taurine, mix 30min
Embodiment 5：
Prescription：
Erythromycin thiocyanate 5g
Taurine 5g
Lactose adds to 100g
Carry out according to the following steps：
(1) erythromycin thiocyanate, glucose and taurine are weighed by described weight；
(2) first by erythromycin thiocyanate ultramicro grinding, Task-size Controlling is below 50 μm, standby；
(3) finally the material after smashing is mixed with lactose and taurine, mix 30min
Embodiment 6：
Prescription：
Erythromycin thiocyanate 5g
Taurine 10g
Soluble starch adds to 100g
Carry out according to the following steps：
(1) erythromycin thiocyanate, glucose and taurine are weighed by described weight；
(2) first by erythromycin thiocyanate ultramicro grinding, Task-size Controlling is below 50 μm, standby；
(3) finally the material after smashing is mixed with soluble starch and taurine, mix 30min
Embodiment 7
Liver protective effect test of the present invention：
Animal used as test selects：Wistar rat, male and female half and half, totally 90, weight 180～220g；Real by Tianjin
Testing animal center provides.
Packet and dose design：Experiment is divided into three groups every group 30 mouse to be：The erythromycin thiocyanate group of 5 multiple doses, 5 times
Dosage plus taurine erythromycin thiocyanate and blank control group.Erythromycin thiocyanate clinic maximum dose level is 0.45g/
(kg d), convert the dosage for erythromycin thiocyanate group by rat and chicken dose,equivalent 5 times, the embodiment of the present invention 1 arrives
With erythromycin thiocyanate group (50% erythromycin thiocyanate, auxiliary material is oral glucose), blank dosage group then feeds 5 to 5 groups of consumptions
Pharmaceutic adjuvant in addition to erythromycin thiocyanate with taurine in the embodiment of the present invention 1 of multiple dose, and normally feeding and drinking-water.
Three groups of equal drug administrations of mouse 7 days.
Pathological examination：Three groups of whole mouse are all carried out with gross anatomy, observe liver, courage histoorgan volume, color and
Quality etc. changes, and the organ changing is fixed with 40g/L formalin, FFPE, section, carries out histopathology inspection
Look into, the Morphology of observation of cell and tissue, determine lesion nature and according to Histopathology standards of grading method difference
Record the area in the visual field shared by various pathologies in each visual field, calculate pathology score, and it is total to accumulate the pathology in the observed visual field
Point.Result is as follows：
Experimental result：
Find that Normal group (non-drug administration) rat lobuli hepatis structure is complete by zoopery, liver rope arrangement rule
Then, liver cell no abnormality seen, hepatic tissue average is (0.0 ± 1.0) point；And it is solvable by dosage erythromycin thiocyanate to take 5
Property powder rat hepatocytes are all shown in there are the phenomenons such as different degrees of swelling.Compared with Normal group, medication group liver tissues of rats
Pathology average (2.2 ± 1.0) is notable to be raised, the statistically significant (P of difference<0.01).And take 5 by the taurine of dosage
Erythromycin thiocyanate soluble powder is compared and is taken merely the liver tissues of rats pathology of erythromycin thiocyanate soluble powder group averagely
(0.7 ± 1.0) is divided to significantly reduce, difference is statistically significant.The erythromycin thiocyanate solubility of taurine is added in explanation accordingly
Powder is stagnant for the bile stasis of blood, and the phenomenon of liver enlargement has obvious mitigation.
Hepatoprotective agent refers to liver protecting function, promotes liver cell regeneration, enhancing liver detoxification function, raising body to exempt from
The medicine of the effects such as epidemic disease power, its species is various, but conventional hepatoprotective agent substantially can be divided into removing toxic substances class, stimulated hepatic cell regeneration class,
Promote energetic supersession class, cholagogic class, Chinese herbal medicine and its extract etc..But erythromycin thiocyanate mainly has hepatotoxicity wind agitation shows as courage
Juice deposits, and therefore adds hepatic and should be directed to this symptom.Although other kinds of hepatic also has good protect liver making
With, but the mitigation to cholestasis is little.
And promoting choleresis, mitigate in the medicine of cholestatis representative have taurine, urso,
Anethol Trithione, Ademetionine, wherein urso are relatively infrequently and expensive in pharmaceutical preparation not to be suitable on a large scale
Production and application, Anethol Trithione is slightly soluble in water and is not suitable for adding in erythromycin thiocyanate soluble powder, and Ademetionine is then
Potential blood ammonia is had to increase risk and easily make animal body produce allergic reaction.
In sum taurine be a kind of cheap and advanced widely used can solubization strong liver cholagogic class medicine, and this
Body also has antiinflammatory action, can reach perfect supplementary result to the antiphlogistic effects of erythromycin thiocyanate；In addition taurine can promote
Entering pituitary hormone secretion, activate pancreas function, thus improving the state of organism endocrine system, promoting sending out of erythromycin drug effect
Wave, therefore the present invention solves the problems, such as that erythromycin thiocyanate injures to liver.
Claims (3)
1. a kind of animal compound erythromycin thiocyanate soluble powder is it is characterised in that described animal compound erythromycin thiocyanate is solvable
Property powder includes the component of following mass percent：Erythromycin thiocyanate 5～50%, taurine 5～10%, balance of auxiliary material.
2. described a kind of animal compound erythromycin thiocyanate soluble powder as arbitrary in claim 1 is it is characterised in that described auxiliary
Expect for DEXTROSE ANHYDROUS, oral glucose, lactose, maltodextrin, add one of beneficial powder, soluble starch or more than one groups
Close.
3. a kind of animal compound erythromycin thiocyanate soluble powder as claimed in claim 1, its preparation process is：
(1) erythromycin thiocyanate, auxiliary material and taurine are weighed by described weight；
(2) first by erythromycin thiocyanate ultramicro grinding, Task-size Controlling is below 50 μm, standby；
(3) finally the material after smashing is mixed, mix 30min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610770352.4A CN106389454A (en) | 2016-08-30 | 2016-08-30 | Compound erythromycin thiocyanate soluble powder for livestock and preparation method therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610770352.4A CN106389454A (en) | 2016-08-30 | 2016-08-30 | Compound erythromycin thiocyanate soluble powder for livestock and preparation method therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106389454A true CN106389454A (en) | 2017-02-15 |
Family
ID=58002166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610770352.4A Pending CN106389454A (en) | 2016-08-30 | 2016-08-30 | Compound erythromycin thiocyanate soluble powder for livestock and preparation method therefor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106389454A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108324690A (en) * | 2018-05-08 | 2018-07-27 | 厦门汇承科技有限公司 | Water-soluble hydrochloric acid sarafloxacin soluble powder for animals of one kind and preparation method thereof |
| CN111714470A (en) * | 2020-05-27 | 2020-09-29 | 天津瑞益瑞美生物技术有限公司 | Sustained-release ethylenediamine tetraacetic acid iron sodium premix for animals and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103099812A (en) * | 2013-01-21 | 2013-05-15 | 湖北武当动物药业有限责任公司 | Medicine for treating porcine reproductive and respiratory syndrome and preparation method thereof |
| CN105147620A (en) * | 2015-10-28 | 2015-12-16 | 保定冀中药业有限公司 | Erythromycin thiocyanate soluble powder and preparation method thereof |
| CN105287477A (en) * | 2015-09-16 | 2016-02-03 | 四川伴农动保生物技术有限公司 | Carbasalate calcium powder and preparation method thereof |
-
2016
- 2016-08-30 CN CN201610770352.4A patent/CN106389454A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103099812A (en) * | 2013-01-21 | 2013-05-15 | 湖北武当动物药业有限责任公司 | Medicine for treating porcine reproductive and respiratory syndrome and preparation method thereof |
| CN105287477A (en) * | 2015-09-16 | 2016-02-03 | 四川伴农动保生物技术有限公司 | Carbasalate calcium powder and preparation method thereof |
| CN105147620A (en) * | 2015-10-28 | 2015-12-16 | 保定冀中药业有限公司 | Erythromycin thiocyanate soluble powder and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 中国兽药典委员会编: "《中华人民共和国兽药典 兽药使用指南 化学药品卷 2010年版》", 30 April 2011, 中国农业出版社 * |
| 周翠珍主编: "《动物药理学》", 31 August 2007, 重庆大学出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108324690A (en) * | 2018-05-08 | 2018-07-27 | 厦门汇承科技有限公司 | Water-soluble hydrochloric acid sarafloxacin soluble powder for animals of one kind and preparation method thereof |
| CN111714470A (en) * | 2020-05-27 | 2020-09-29 | 天津瑞益瑞美生物技术有限公司 | Sustained-release ethylenediamine tetraacetic acid iron sodium premix for animals and preparation method thereof |
| CN111714470B (en) * | 2020-05-27 | 2022-04-08 | 天津瑞益瑞美生物技术有限公司 | Enteric-coated sodium iron ethylene diamine tetraacetate premix for livestock and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103006792B (en) | A kind of herbal medicine for preventing and treating livestock and poultry intestinal canal diseases and preparation method thereof and feed | |
| CN101934070A (en) | Veterinary antibacterial drug composition containing lysozyme and oligosaccharide and application thereof | |
| CN101496811B (en) | Soluble and stable tilmicosin composition | |
| CN100586441C (en) | Compound sulfamonomethoxine sodium injection and preparation method thereof | |
| CN101991640A (en) | Preparation method of mahonia fortune-containing Chinese medicinal composition and application thereof | |
| CN106389454A (en) | Compound erythromycin thiocyanate soluble powder for livestock and preparation method therefor | |
| CN101209296A (en) | Chinese medicinal granule with worm-expelling liver-caring, hemostasis and dysentery-stopping efficacy | |
| WO2005074952A1 (en) | Chinese medicine for treatment of irritable bowel sysndrome and the preparation thereof | |
| CN103446312A (en) | Compound poplar flower oral liquid and preparation method thereof | |
| CN102379939B (en) | Drug composition for preventing and treating exogenous fever of livestock and poultry | |
| KR101965591B1 (en) | Composition for inhibiting activity of amylase containing chitooligosaccharide | |
| CN102247390B (en) | Medicine for treating bacterial air sacculitis in livestock and preparation method thereof | |
| CN101987117A (en) | Traditional Chinese medicine composition for treating bacterial diseases in poultry and livestock and preparation method thereof | |
| CN100425229C (en) | Local medicine preparation containing antiinfective medicine composition and its preparing method | |
| CN105770054A (en) | Pharmaceutical composition for preventing and treating chicken coccocidiosis, additive and feed | |
| CN115721678B (en) | Pharmaceutical composition for treating or preventing necrotic enteritis of chickens and application thereof | |
| WO2012131650A1 (en) | Herbal compositions of coccinia indica for treatment or prevention of inflammatory diseases | |
| CN107308439A (en) | A kind of compound poplar flower oral liquid and preparation method thereof | |
| CN103272068B (en) | Chinese and western medicine compound preparation containing tilmicosin and preparation method thereof | |
| CN102379945B (en) | Veterinary compound Chinese-western drug composition for defervescing and diminishing inflammation | |
| EP2606902A1 (en) | Rhus copallina extract as medicine | |
| CN108042690B (en) | Traditional Chinese medicine composition for treating swine mycoplasmal pneumonia and application thereof | |
| CN102416169A (en) | Composition used for alimentary tract diseases of poultry | |
| CN101450066A (en) | Soluble powder for treating poultry bacterial and mycoplasma infection | |
| CN109793838A (en) | A kind of plaster and preparation method thereof for preventing and treating chiru sheep mouth inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170215 |